Skip to main content
. 2019 Feb 22;8(2):270. doi: 10.3390/jcm8020270

Figure 2.

Figure 2

Flowchart summarizing soluble ST2 (sST2) aided therapeutic decision-making for patients with type 1 myocardial infarction. In patients with type 1 acute myocardial infarction (AMI), sST2 levels can help to identify 3 classes of patients. If sST2 <35 ng/mL, adverse remodeling is unlikely. In patients with 35 ≤ sST2 ≤ 70 ng/mL, adverse remodeling is more likely, and patients could benefit from antifibrotic therapies. If sST2 >70 ng/mL, adverse remodeling is fairly common, requiring aggressive anti-remodeling therapies. Suggested actions for each class of patients are shown in the panels below.